Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 597.54 Million SEK | 43.88% |
| 2022 | 415.29 Million SEK | 60.73% |
| 2021 | 258.38 Million SEK | 43.66% |
| 2020 | 179.86 Million SEK | -18.56% |
| 2019 | 220.83 Million SEK | 17.55% |
| 2018 | 187.86 Million SEK | 26.65% |
| 2017 | 148.34 Million SEK | 7.36% |
| 2016 | 138.17 Million SEK | 14.91% |
| 2015 | 120.24 Million SEK | 41.96% |
| 2014 | 84.7 Million SEK | 22.9% |
| 2013 | 68.92 Million SEK | 368.09% |
| 2012 | 14.72 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 186.02 Million SEK | 19.44% |
| 2024 Q2 | 210.34 Million SEK | 13.08% |
| 2024 Q3 | 198.48 Million SEK | -5.64% |
| 2023 Q4 | 155.74 Million SEK | 6.22% |
| 2023 Q3 | 146.61 Million SEK | -5.15% |
| 2023 Q1 | 140.61 Million SEK | 6.92% |
| 2023 Q2 | 154.57 Million SEK | 9.93% |
| 2023 FY | 597.54 Million SEK | 43.88% |
| 2022 Q1 | 92.65 Million SEK | 7.91% |
| 2022 FY | 415.29 Million SEK | 60.73% |
| 2022 Q4 | 131.51 Million SEK | 35.81% |
| 2022 Q3 | 96.83 Million SEK | 2.7% |
| 2022 Q2 | 94.28 Million SEK | 1.76% |
| 2021 Q2 | 59.26 Million SEK | 1.61% |
| 2021 Q4 | 85.86 Million SEK | 56.3% |
| 2021 Q3 | 54.93 Million SEK | -7.3% |
| 2021 FY | 258.38 Million SEK | 43.66% |
| 2021 Q1 | 58.32 Million SEK | -3.24% |
| 2020 FY | 179.86 Million SEK | -18.56% |
| 2020 Q2 | 30.39 Million SEK | -34.58% |
| 2020 Q3 | 42.73 Million SEK | 40.61% |
| 2020 Q4 | 60.27 Million SEK | 41.05% |
| 2020 Q1 | 46.45 Million SEK | -25.57% |
| 2019 Q1 | 47.65 Million SEK | -18.39% |
| 2019 FY | 220.83 Million SEK | 17.55% |
| 2019 Q3 | 54.33 Million SEK | -3.73% |
| 2019 Q4 | 62.41 Million SEK | 14.88% |
| 2019 Q2 | 56.43 Million SEK | 18.44% |
| 2018 Q1 | 42.47 Million SEK | 2.18% |
| 2018 FY | 187.86 Million SEK | 26.65% |
| 2018 Q4 | 58.38 Million SEK | 42.71% |
| 2018 Q3 | 40.91 Million SEK | -11.23% |
| 2018 Q2 | 46.09 Million SEK | 8.51% |
| 2017 Q2 | 37.03 Million SEK | -1.18% |
| 2017 Q1 | 37.47 Million SEK | -2.45% |
| 2017 FY | 148.34 Million SEK | 7.36% |
| 2017 Q4 | 41.56 Million SEK | 28.84% |
| 2017 Q3 | 32.26 Million SEK | -12.88% |
| 2016 Q2 | 34.49 Million SEK | 2.88% |
| 2016 Q1 | 33.53 Million SEK | 2.6% |
| 2016 FY | 138.17 Million SEK | 14.91% |
| 2016 Q4 | 38.41 Million SEK | 21.08% |
| 2016 Q3 | 31.73 Million SEK | -8.02% |
| 2015 Q2 | 29.12 Million SEK | -8.46% |
| 2015 Q1 | 31.82 Million SEK | 24.57% |
| 2015 FY | 120.24 Million SEK | 41.96% |
| 2015 Q4 | 32.68 Million SEK | 22.77% |
| 2015 Q3 | 26.61 Million SEK | -8.61% |
| 2014 FY | 84.7 Million SEK | 22.9% |
| 2014 Q4 | 25.54 Million SEK | 13.89% |
| 2014 Q2 | 18.47 Million SEK | 1.18% |
| 2014 Q1 | 18.25 Million SEK | -8.86% |
| 2014 Q3 | 22.42 Million SEK | 21.4% |
| 2013 Q4 | 20.03 Million SEK | 19.35% |
| 2013 Q2 | 15.77 Million SEK | -3.38% |
| 2013 FY | 68.92 Million SEK | 368.09% |
| 2013 Q1 | 16.32 Million SEK | 10.9% |
| 2013 Q3 | 16.78 Million SEK | 6.38% |
| 2012 Q4 | 14.72 Million SEK | 0.0% |
| 2012 FY | 14.72 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -9474.459% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 56.479% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 56.479% |
| Arcoma AB | 163.01 Million SEK | -266.556% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -192.927% |
| BICO Group AB (publ) | 2.23 Billion SEK | 73.318% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | -4.588% |
| CellaVision AB (publ) | 677.29 Million SEK | 11.775% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -7122.797% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -61105.944% |
| C-Rad AB (publ) | 424.61 Million SEK | -40.726% |
| Duearity AB (publ) | 1.65 Million SEK | -36027.086% |
| Dignitana AB (publ) | 86.06 Million SEK | -594.308% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -5701.379% |
| Getinge AB (publ) | 31.82 Billion SEK | 98.123% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -8341.9% |
| Integrum AB (publ) | 104.11 Million SEK | -473.905% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -69812.566% |
| Mentice AB (publ) | 273.61 Million SEK | -118.392% |
| OssDsign AB (publ) | 112.15 Million SEK | -432.773% |
| Paxman AB (publ) | 210.11 Million SEK | -184.385% |
| Promimic AB (publ) | 37.07 Million SEK | -1511.929% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -244794.262% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -2470.626% |
| ScandiDos AB (publ) | 60.42 Million SEK | -888.833% |
| Sectra AB (publ) | 2.96 Billion SEK | 79.837% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -288.35% |
| Senzime AB (publ) | 35.75 Million SEK | -1571.259% |
| SpectraCure AB (publ) | 318 Thousand SEK | -187806.289% |
| Stille AB | 294.89 Million SEK | -102.63% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 82.986% |